Arcturus Therapeutics Holdings Inc.
ARCT
$6.72
$0.172.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 82.03M | 97.60M | 122.12M | 143.68M | 152.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 82.03M | 97.60M | 122.12M | 143.68M | 152.31M |
| Cost of Revenue | 112.21M | 131.52M | 147.39M | 176.48M | 195.16M |
| Gross Profit | -30.18M | -33.92M | -25.26M | -32.80M | -42.85M |
| SG&A Expenses | 46.08M | 44.43M | 47.31M | 49.29M | 52.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 158.29M | 175.95M | 194.70M | 225.76M | 247.98M |
| Operating Income | -76.26M | -78.35M | -72.57M | -82.08M | -95.67M |
| Income Before Tax | -65.78M | -66.71M | -60.38M | -68.57M | -80.94M |
| Income Tax Expenses | 0.00 | 0.00 | -217.00K | -371.00K | -3.00K |
| Earnings from Continuing Operations | -65.78 | -66.71 | -60.16 | -68.20 | -80.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.78M | -66.71M | -60.16M | -68.20M | -80.94M |
| EBIT | -76.26M | -78.35M | -72.57M | -82.08M | -95.67M |
| EBITDA | -73.24M | -75.19M | -69.26M | -78.64M | -92.13M |
| EPS Basic | -2.39 | -2.46 | -2.22 | -2.52 | -3.00 |
| Normalized Basic EPS | -1.49 | -1.54 | -1.40 | -1.59 | -1.88 |
| EPS Diluted | -2.39 | -2.46 | -2.22 | -2.52 | -3.00 |
| Normalized Diluted EPS | -1.49 | -1.54 | -1.40 | -1.59 | -1.88 |
| Average Basic Shares Outstanding | 109.54M | 108.42M | 108.30M | 108.14M | 107.91M |
| Average Diluted Shares Outstanding | 109.54M | 108.42M | 108.30M | 108.14M | 107.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |